CardioQ update

Deltex Medical Group PLC
14 April 2008

                            Deltex Medical Group plc

   Largest audit of the CardioQ(TM) in 'fast-track' bowel surgery set to expand

14 April 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, today announces that doctors in Spain
undertaking the largest ever audit of the impact of the Company's CardioQ
oesophageal Doppler monitor (ODM) are expanding the number of hospitals involved
in the project.

Dr Jose Manuel Ramirez, one of Spain's most senior surgeons and a specialist in
bowel surgery at the University Hospital in Zaragoza, is leading the audit which
will examine changes in the numbers of complications and lengths of stay in
patients undergoing major bowel surgery using the CardioQ in a 'fast-track'
surgery setting compared to historical data for patients undergoing similar
surgery using traditional approaches to care.

'Fast-track' or 'enhanced recovery' protocols combine elements of best practice
in surgical techniques and patient care to keep patients as well as possible
immediately before, during and after their surgery.

Originally planned to be conducted across seven hospitals in Spain, interest in
this independent project, organised and supervised by the University of Zaragoza
has been such that Dr Ramirez felt it appropriate to expand this to include a
further four hospitals, although many more expressed strong interest in being
involved.

Deltex Medical has been working closely with Dr Ramirez and his colleagues and
training at the first group of hospitals is now complete. The new sites will be
trained over the coming weeks. Data collection will begin on 1 May 2008 and is
expected to conclude at the end of October, in time for presentation of the
results at the Spanish National Congress of Surgery in Madrid in November 2008.

Dr Ramirez commented:

'Surgeons have added strategies during surgery designed to enhance patients'
recovery still further. They use minimally invasive surgical techniques and
epidural anaesthesia wherever possible and precise cardiac and fluid monitoring
during operations through an oesophageal Doppler probe used with CardioQ, which
monitors blood flow from the heart. In elective complex surgical procedures
these approaches have been shown in trials to lead to a lower rate of
postoperative complications and shorten time to recovery and hospital stay, our
objective is to promote and press forward with these programmes in the field of
general and digestive surgery'

The Spanish Agencia Lain Entralgo para la Formacion, Investigacion y Estudios
Sanitarios de la Comunidad de Madrid, Spain's equivalent to the UK's National
Institute for Health and Clinical Excellence (NICE), is closely involved in the
audit project and its remit includes making recommendations on a national basis
about which new technologies should become integrated as routine practice in the
Spanish health service.

Mr. Juan Antonio Blasco Amaro, who is responsible for medical device evaluation
at the Agencia Lain Entralgo para la Formacion, Investigacion y Estudios
Sanitarios de la Comunidad de Madrid commented:

'The outcome of this study could make the CardioQ a specification and preferable
device of use included in the social security health program'

Deltex Medical's Chief Executive, Andy Hill commented:

'Fast-track and enhanced recovery programmes are gaining ground as the standard
of care for patients having bowel and other major surgical procedures. Dr
Ramirez's project has the very real potential to accelerate substantially the
adoption of this approach across more than 200 hospitals in Spain performing
this kind of surgery.'

For further information, please contact:-

Deltex Medical Group plc                        01243 774 837
Nigel Keen, Chairman                            [e-mail]
Andy Hill, Chief Executive                      [e-mail]
Ewan Phillips, Finance Director                 [e-mail]

Gavin Anderson & Company                        0207 554 1400
Deborah Walter                                  [e-mail]
Robert Speed                                    [e-mail]
Stuart Macaulay                                 [e-mail]

Charles Stanley Securities
Nominated Advisors                              020 7149 6000
Philip Davies                                   [e-mail]
Russell Cook                                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to optimise
critically ill patients and those undergoing routine moderate to major surgery
through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been proven to improve the speed and quality of patient
recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange